Related references
Note: Only part of the references are listed.CD28 superagonists: What makes the difference in humans?
Burkhart Schraven et al.
IMMUNITY (2008)
Toward experimental assessment of receptor occupancy: TGN1412 revisited
Zoe Waibler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
CTLA-4: Negative regulator of the immune response and a target for cancer therapy
Ulrich Keilholz
JOURNAL OF IMMUNOTHERAPY (2008)
Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
Zoe Waibler et al.
PLOS ONE (2008)
The effects of antibody treatment on regulatory CD4(+)CD25(+) T cells
Huanfa Yi et al.
TRANSPLANT IMMUNOLOGY (2008)
Studies of monkey complement: Measurement of cynomolgus monkey CH50, ACH50, C4, C2 and C3
Hengjie Xu et al.
XENOTRANSPLANTATION (2008)
Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics
Hugo M. Vargas et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2008)
Innovative early development regulatory approaches: expIND, expCTA, microdosing
W. T. Robinson
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
High-risk molecules or insufficient scientific data?
A. Mignot
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug
James S. Bourdage et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development
P. J. Lowe et al.
XENOBIOTICA (2007)
Cytokine Storm in the phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics
Richard Stebbings et al.
JOURNAL OF IMMUNOLOGY (2007)
Preclinical and clinical safety of monoclonal antibodies
Mohammad A. Tabrizi et al.
DRUG DISCOVERY TODAY (2007)
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
Gopi Shankar et al.
NATURE BIOTECHNOLOGY (2007)
Immunostimulatory monoclonal antibodies for cancer therapy
Ignacio Melero et al.
NATURE REVIEWS CANCER (2007)
Toxicity as a result of immunostimulation by biologics
Elizabeth J. Gribble et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2007)
Antibody therapeutics: isotype and glycoform selection
Roy Jefferis
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
IgG fc receptor III homologues in nonhuman primate species: Genetic characterization and ligand interactions
Kenneth A. Rogers et al.
JOURNAL OF IMMUNOLOGY (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Loss of Siglec expression on T lymphocytes during human evolution
Dzung H. Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
TGN1412 -: a regulator's perspective
CK Schneider et al.
NATURE BIOTECHNOLOGY (2006)
Elimination mechanisms of therapeutic monoclonal antibodies
MA Tabrizi et al.
DRUG DISCOVERY TODAY (2006)
Siglecs in innate immunity
PR Crocker
CURRENT OPINION IN PHARMACOLOGY (2005)
STP position paper: Best practice guideline for the routine pathology evaluation of the immune system
P Haley et al.
TOXICOLOGIC PATHOLOGY (2005)
Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody
J Clarke et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2004)
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products
AR Mire-Sluis et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide
SP Henry et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2002)
Idiotypic-anti-idiotypic complexes and their in vivo metabolism
A Johansson et al.
CANCER (2002)
A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer
G Rosati et al.
ONCOLOGY (2002)
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2000)
Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFα monoclonal antibody
G Treacy
HUMAN & EXPERIMENTAL TOXICOLOGY (2000)
Share Paper
